Opportunities
Search

Buyer: МНОГОПРОФИЛНА БОЛНИЦА ЗА АКТИВНО ЛЕЧЕНИЕ - СВЕТИ НИКОЛАЙ ЧУДОТВОРЕЦ ЕООД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-11-14

Buyer: LESY Slovenskej republiky, štátny podnik | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2027-11-15

The purpose of this Notice of Funding Opportunity (NOFO) is to leverage NICHD clinical research Network infrastructure relevant to infants, children, women, pregnant and lactating women, and persons with disabilities to conduct innovative, multisite, investigator-initiated clinical trials and observational studies. This NOFO will utilize a bi-phasic (UG3/UH3), milestone-driven mechanism consisting of a start-up phase (UG3) and a full enrollment and clinical trial implementation phase (UH3). Applications submitted in response to this NOFO must address specific aims and milestones for both the UG3 and UH3 phases. A UG3 project (phase I) that meets its milestones will be administratively considered by NICHD and prioritized for transition to the UH3 award (phase II). This NOFO provides an opportunity to leverage NICHD clinical research Network infrastructure as a platform for investigator-initiated innovative hypotheses by any investigator in the extramural community. Applications must be submitted as investigator-initiated, multi-Project Director/Principal Investigator (PD/PI) grant applications in conjunction with the respective NICHD-supported Network Data Coordinating Center (DCC), or equivalent as determined by the NICHD.

Through this Notice of Funding Opportunity (NOFO), entitled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), the National Cancer Institute (NCI) encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are designed to mature experimental nanomedicines relying on nanoparticles and nano-devices which demonstrate strong potential to improve cancer treatment effectiveness due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which is delivered. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.

The purpose of this notice of funding opportunity (NOFO) is to solicit applications for pilot projects to elucidate a role for understudied proteins in rare disease. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s). A list of eligible proteins is provided and are members of druggable protein families that have a known association with a rare disease. This NOFO is intended to jumpstart research on understudied proteins that are associated with rare diseases and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins within the context of rare disease.

This Notice of Funding Opportunity (NOFO) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This NOFO is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.

This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

This Notice of Funding Opportunity (NOFO) invites applications for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently outlined by the NIH Office of AIDS Research (OAR) in NOT-20-018, UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding, scientific priorities. Potential topics could address multiple overarching priorities. These include elucidation of unique pathophysiological mechanisms contributing to HIV comorbidities, coinfections, and complications (CCCs) affecting organs, tissues, and processes within the mission of the NIDDK. Likewise, interrogations into biological mechanisms underlying HIV reservoirs in NIDDK-relevant tissues are important for developing strategies for long-term viral suppression or eradication. Finally, health-impeding social determinants of health may affect CCCs or viral reservoirs within NIDDK's mission through multiple pathways.

Buyer: MARIANUM - Pohrebníctvo mesta Bratislavy | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-11-17

This notice of funding opportunity (NOFO) will support research towards understanding and mitigating the deleterious effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids (e.g., fentanyl, carfentanil, nitazenes) and their combinations (fentanyl and xylazine). This NOFO will also support research on the persistent and/or delayed pathophysiological effects after acute exposure to such agents.

Buyer: Lietuvos šaulių sąjunga | Notice type: cn-social | Procedure: restricted | Contract: services | Deadline: 2027-11-20

Buyer: Lietuvos šaulių sąjunga | Notice type: cn-social | Procedure: restricted | Contract: services | Deadline: 2027-11-20

Buyer: VĮ Turto bankas | Notice type: cn-standard | Procedure: restricted | Contract: works | Deadline: 2027-11-24

Buyer: Dirección General de Recursos Económicos del Servicio Canario de la Salud | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-11-25

Buyer: MARIANUM - Pohrebníctvo mesta Bratislavy | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2027-11-26

Buyer: МНОГОПРОФИЛНА БОЛНИЦА ЗА АКТИВНО ЛЕЧЕНИЕ - Д-Р СТАМЕН ИЛИЕВ АД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-11-26

Buyer: AOK Niedersachsen. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-11-27

Buyer: AOK Niedersachsen. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-11-27

Buyer: AOK Niedersachsen. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-11-27

Buyer: AOK Niedersachsen. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-11-27

Buyer: AOK Niedersachsen. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-11-27

Buyer: AOK Niedersachsen. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-11-27

Buyer: AOK Niedersachsen. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-11-27

Buyer: AOK Niedersachsen. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-11-27